CAR-T(CAR-T)细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T(CAR-T)细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:A bibliometric and scientific knowledge-map study of the chimeric antigen receptor (CAR) natural killer (NK) cell-related research from 2010 to 2022.
A bibliometric and scientific knowledge-map study of the chimeric antigen receptor (CAR) natural killer (NK) cell-related research from 2010 to 2022.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
在本研究中,文献计量学和科学知识图谱研究为 CAR-NK 细胞领域提供了独特而客观的视角。这些信息将为对该领域感兴趣的研究人员提供有益的参考。
作为CAR-T 细胞治疗之后新兴的过继性免疫疗法,CAR-NK细胞治疗近年来发展迅速。目前,CAR-NK细胞的研究已成为肿瘤免疫治疗领域的热点。
在这项描述性研究中,使用CiteSpace和VOSviewer对与CAR-NK细胞相关的文章和综述进行了文献计量学和科学知识图谱分析。
来自65个国家715个机构的5371位作者在346种期刊上发表了1028篇关于CAR-NK细胞的论文。CAR-NK细胞相关出版物数量总体呈增长趋势,尤其是2018年至2021年。美国处于领先地位。最活跃的机构是Univ Texas, MD Anderson Cancer Center(美国)。发文量最多的期刊是Frontiers in immunology,共被引最多的期刊是Blood。发表论文最多的研究者是Winfried S. Wels,而共被引最多的研究者是Shannon L Maude。CAR-NK细胞在血液系统恶性肿瘤和实体瘤中的研究(尤其是靶点选择以及疗效和安全性评估)是该领域的研究热点。新兴主题主要包括三个方面。第一,进一步提高NK细胞在体内的增殖和持久性。第二,优化和改进用于NK细胞的CAR结构,以提高CAR-NK细胞的抗肿瘤能力。第三,CRISPR/Cas9基因编辑技术在构建工程化免疫细胞中的相关研究。
As emerging adoptive immunotherapy after CAR-T cell therapy, CAR-NK cell therapy has been developing rapidly in recent years. Presently, the research on CAR-NK cells has become a hotspot in the field of tumor immunotherapy.
In this descriptive study, CtieSpace and VOSviewer were used to perform the bibliometric and scientific knowledge-map analysis of articles and reviews related to CAR-NK cells.
5371 authors from 715 institutions in 65 countries published 1028 papers about CAR-NK cells in 346 journals. The number of publications related to CAR-NK cells was increasing overall, especially from 2018 to 2021. The United States was in a leading position. The most active institution was Univ Texas, MD Anderson Cancer Center (USA). The journal with the most publications was Frontiers in immunology , and the most co-cited journal was Blood . The researcher with the most published papers was Winfried S. Wels, while the most co-cited researcher was Shannon L Maude. The research of CAR-NK cells in hematological malignancies and solid tumors (especially the selection of targets and the evaluation of efficacy and safety) was a research hotspot in this field. The emerging topics mainly included three aspects. First, further improve the proliferation and persistence of NK cells in vivo . Secondly, optimizing and improving the CAR structure for NK cells to improve the anti-tumor ability of CAR-NK cells. Thirdly, the related research of CRISPR/Cas9 gene-editing technology in constructing engineered immune cells.
In this study, a bibliometric and scientific knowledge-map study provided a unique and objective perspective for the CAR-NK cell field. This information would provide a helpful reference for researchers interested in this field.
在 PubMed 查看 → 出版商原文(DOI) 全文 PDF(PMC)· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。